Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survival

Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survival

Background and Purpose: Pembrolizumab has now become a standard of care in metastatic urothelial carcinoma (mUC), although the treatment effect of the drug substantially differs among individuals. Emerging evidence suggests that radiotherapy exerts a synergistic effect with PD-1 blockade. We sought...

Full description

Bibliographic Details
Main Authors: Keita Nakamori, Shogo Yamazaki, Kazumasa Komura, Wataru Fukuokaya, Takahiro Adachi, Yosuke Hirasawa, Takeshi Hashimoto, Atsuhiko Yoshizawa, Takaya Ohno, Yusuke Yano, Kazuki Nishimura, Satoshi Tokushige, Taizo Uchimoto, Shutaro Yamamoto, Kosuke Iwatani, Fumihiko Urabe, Keiichiro Mori, Takafumi Yanagisawa, Shunsuke Tsuduki, Kiyoshi Takahara, Teruo Inamoto, Jun Miki, Takahiro Kimura, Yoshio Ohno, Ryoichi Shiroki, Haruhito Azuma
Format: Article
Language:English
Published: Elsevier 2023-03-01
Series:Clinical and Translational Radiation Oncology
Online Access:http://www.sciencedirect.com/science/article/pii/S2405630822001161

Internet

http://www.sciencedirect.com/science/article/pii/S2405630822001161

Similar Items